Zanidatamab

Zymeworks Inc. (ZYME), a biopharmaceutical company, focuses on cancer treatment through biotherapeutics. Key products include zanidatamab and zanidatamab zovodotin, targeting HER2 in various clinical trial phases. With strategic partnerships and a market cap of $973.239M, ZYME is advancing in oncology and immuno-oncology, despite a negative EPS of -1.49 and a profit margin of -182.75%.

Zymeworks anticipates IND applications for ZW220 and ZW251 in 2025, and for ZW209 and ZW1528 in 2026. Phase 3 results for Ziihera® in HER2-positive GEA expected 2Q-2025, with potential sBLA submission. Regulatory decisions for zanidatamab in BTC in EU and China as early as 2Q-2025. $324M cash as of Dec 31, 2024, with runway into 2H-2027. Expanding R&D into AIID and hematological cancers.

Liberty Defense's HEXWAVE system selected for a trial in a Middle Eastern US ally to detect explosive threats, including metallic and non-metallic materials, for border security, check-points, and military applications. K92 Mining reports record Q4 and annual production, exceeding guidance, with high metallurgical recoveries and increased mine development rates.

Zymeworks outlines 2025-2026 strategic priorities, including new drug applications for solid tumor treatments, expecting regulatory decisions and clinical trial results. With FDA-approved zanidatamab and a strong financial outlook, it aims to expand into autoimmune, inflammatory diseases, and hematological cancers.

Zymeworks (ZYME) updates on strategic priorities for 2025-2026, including new drug applications for solid tumors, regulatory decisions, and clinical trial results. With FDA approval of zanidatamab and a focus on autoimmune diseases and hematological cancers, Zymeworks aims to strengthen its R&D pipeline and market position.

Zymeworks anticipates IND applications for ZW220 and ZW251 in 2025, and for ZW209 and ZW1528 in 2026. Phase 3 results for Ziihera® in HER2-positive GEA expected 2Q-2025, with potential sBLA submission. Regulatory decisions for zanidatamab in BTC expected as early as 2Q-2025. Cash resources of $324M as of Dec 31, 2024, projected to fund operations into 2H-2027. Company to present at J.P. Morgan Healthcare Conference on Jan 16, 2024.

Zymeworks plans IND applications for ZW220 and ZW251 in 2025, and ZW209 and ZW1528 in 2026. Anticipates Phase 3 HERIZON-GEA-01 results and sBLA for Ziihera® in 2025. Projects cash runway into 2H-2027 with $324M as of Dec 31, 2024. Aims to expand R&D into AIID and hematological cancers.